Merck’s Keytruda combo wows again, acing PhIII overall survival goal for lung cancer early
Merck’s Keytruda team can chalk up another big win in the race for PD-1/L1 dominance.
Their checkpoint inhibitor added to chemo in a pivotal study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
